American Society of Hematology

Figure 3

$Figure 3. miR-26a expression in MYC-induced lymphoma. (A,B) Northern blot analyses for miR-26a. (A) miR-26a expression in murine Myc-induced lymphoma cell lines after Dox treatment (18 hours). (B) miR-26a expression in human BL-derived cell lines and peripheral blood derived mononuclear cells (PBMNC). (C) Quantitative RT-PCR results evaluating miR-26a expression in primary human BL (n = 11), unselected B-CLL (n = 9), and CD19+-enriched B-CLL (n = 3) samples as well as in BL-derived cell lines (n = 3) and the CD19− fraction of the 3 enriched B-CLL cases. Normalized expression values are depicted (box plots indicate median expression and range of expression values). There are significant differences between BL and B-CLL samples with regard to miR-26a expression (P < .001, exact Wilcoxon rank sum test).$

miR-26a expression in MYC-induced lymphoma. (A,B) Northern blot analyses for miR-26a. (A) miR-26a expression in murine Myc-induced lymphoma cell lines after Dox treatment (18 hours). (B) miR-26a expression in human BL-derived cell lines and peripheral blood derived mononuclear cells (PBMNC). (C) Quantitative RT-PCR results evaluating miR-26a expression in primary human BL (n = 11), unselected B-CLL (n = 9), and CD19⁺-enriched B-CLL (n = 3) samples as well as in BL-derived cell lines (n = 3) and the CD19⁻ fraction of the 3 enriched B-CLL cases. Normalized expression values are depicted (box plots indicate median expression and range of expression values). There are significant differences between BL and B-CLL samples with regard to miR-26a expression (P < .001, exact Wilcoxon rank sum test).

This Feature Is Available To Subscribers Only